Data sourced from BSE & NSE · Compiled by IPO Ji · IPO subscription data last updated
Total 144.49x·QIB 293.80x·NII 220.18x·Retail 30.29x
Based on retail subscription by applications (24.82×), approximately 1 in 25 retail applications may receive an allotment. Final allotment is decided by the registrar’s computerised lottery.
Corona Remedies Limited Mainboard IPO was subscribed 144.49x in total when bidding closed on Dec 10, 2025, with 293.8x in the QIB category, 220.18x in NII, 30.29x in retail across BSE and NSE. This represents a strong oversubscription, reflecting heavy investor demand; a high subscription figure does not guarantee listing gains, and allotment follows the applicable category and exchange rules. The issue ran from Dec 8, 2025 to Dec 10, 2025 at a price band of ₹1,008–₹1,062 per share. Allotment was finalised on Dec 11, 2025.
| Category | Offer | Applied | Times |
|---|---|---|---|
| QIBs | 1221729 | 358939448 | 293.8 |
| NIIs | 916960 | 201897066 | 220.18 |
| BNIIs (>10L) | 611307 | 150793356 | 246.67 |
| SNIIs (<10L) | 305653 | 51103710 | 167.2 |
| Retail | 2139573 | 64801954 | 30.29 |
| Employee | 58036 | 902888 | 15.56 |
| Total | 4336298 | 626541356 | 144.49 |
| Total Applications42,38,862 approx. |
|||
| Category | Reserve | Applied | Times |
|---|---|---|---|
| BNIIs (>10L) | 3,119 | 1,55,224 | 49.77 |
| SNIIs (<10L) | 1,559 | 2,49,991 | 160.35 |
| Retail | 1,52,827 | 37,92,473 | 24.82 |
| Employee | - | 35,988 | - |
| Total Applications42,38,862 approx. |
|||
| Category | Offered | Demand | Times |
|---|---|---|---|
| QIBs | 129.75 | 38119.37 | 293.8 |
| FIIs | - | 9265.99 | - |
| DIIs | - | 16543.28 | - |
| Mutual Funds | - | 2339.56 | - |
| Others | - | 9970.54 | - |
| NIIs | 97.38 | 21441.47 | 220.18 |
| BNIIs (>10L) | 64.92 | 16014.25 | 246.67 |
| SNIIs (<10L) | 32.46 | 5427.21 | 167.2 |
| Retail | 227.22 | 6881.97 | 30.29 |
| Employee | 6.16 | 95.89 | 15.56 |
| TOTAL | 460.51 | 66538.69 | 144.49 |
| As on | QIB |
NII
bHNI
sHNI
|
Retail | Total |
|---|---|---|---|---|
|
Day 1
8 Dec 2025
5:00 PM
|
0.00x |
0.84x
0.53x
1.45x
|
0.93x | 0.66x |
|
Day 2
9 Dec 2025
5:00 PM
|
1.76x |
28.32x
29.02x
26.92x
|
6.81x | 9.90x |
|
Day 3
10 Dec 2025
5:00 PM
|
293.80x |
220.18x
246.67x
167.20x
|
30.29x | 144.49x |
Anticipated subscription based on the number of applications received (an alternative to the shares-based figures above), sourced from BSE & NSE.
| Category | Times (by applications) |
|---|---|
| bHNI | 49.77x |
| sHNI | 160.35x |
| Retail | 24.82x |
Because Corona Remedies closed oversubscribed, applicants were not guaranteed full allotment. In oversubscribed issues, shares are allotted according to the applicable category and exchange rules, so applicants are not guaranteed full allotment once an issue is oversubscribed. The number of times each category is subscribed is one indicator of demand, alongside the company's fundamentals and the broader market.
A high subscription figure reflects strong demand but does not guarantee a premium listing, and a low figure does not guarantee a discount. This page is for information only and is not investment advice. Investors should read the company's prospectus and consult a SEBI-registered adviser before making any decision.
IPO subscription status shows how many times an issue has been applied for, compared with the shares on offer, broken down by Qualified Institutional Buyers (QIB), Non-Institutional Investors (NII), and the Retail or SME Individual Investor category. A figure of "2x" means investors applied for twice the shares available. See how IPO subscription works and track all live IPOs →
Data Source: The above information / data is sourced from National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) websites and is subject to change in real time. For latest information / data, please refer to the respective websites.
Purpose: The information / data provided herein is for informational purposes only and is provided by ipoji.com on "AS IS" and "AS AVAILABLE" basis and without warranty, express or implied.
Accuracy: ipoji.com does not warrant the accuracy, adequacy or completeness of the information you obtain through the above websites.
Liability: ipoji.com shall not be liable in any way for any discrepancies, errors, omissions, losses or damage. ipoji.com, including its affiliates and its directors, staff and employees, shall not be liable for any loss, damage of any kind, including but not limited to direct, indirect, punitive, exemplary, consequential damages and lost profits arising in any way out of the use of information / data obtained through the said websites.
User Responsibility: The recipient alone is fully responsible / liable for any decision made based on this information / data. All recipients, before relying on the said information, should do their own research and seek appropriate professional advice.